The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | ASCO 2022: ZUMA-2, BCMA-targeting BiTEs & novel CARs in myeloma
Matthew Frigault, MD, Harvard Medical School, Boston, MA, highlights long-term follow-up results of ZUMA-2 (NCT02601313) which evaluated brexucabtagene autoleucel (brexu-cel) CAR-T therapy in R/R mantle cell lymphoma (MCL), new data on the use of BCMA-targeting bispecific T-cell engagers (BiTEs) in multiple myeloma as well as the use of novel CAR-T approaches in myeloma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
